Facet-related spinal pain for non-specific low back pain pose considerable challenge for radiologists and clinicians in finding the right set of interventional tools. The reason has to do with nonspecific clinical features and radiological findings. For patients suffering with facet-joint pain, the condition is debilitating and often leads to physical deconditioning, restricted daily motion, and muscle spasm. In the backdrop of the substantial burden of facet-joint pain, the facet joint injections market has made a swift emergence. A significant proportion of the target population is 30–50 years, which adds to the morbidity. The facet joint injection market has seen the growing traction of imaging-guided injections in outpatient procedures. The injectable consists mainly of local anesthetic and steroids.
Key application segments in the facet joint injections market are cervical facet joints, thoracic facet joints, and lumbar facet joints. In the evolution process, a number of spinal injections have been tested for their effect in reducing pain intensity and improving rehabilitation. There is an unmet need for more research on different injectable and associated outpatient procedures with the goal of improving diagnostic accuracy, safety, and reproducibility.
The study on the facet joint injections market offers critical assessment of key growth dynamics, the market scope on major clinical trials, and clinical trends that have substantial industry potential. The research presents a scrutiny of how the competitive landscape is evolving and the various facets of the adoption of the procedures related to facet joint injections.
The drive for the facet joint injections market stems from the demand for improving the outcomes of the current therapeutics and diagnostics. Growing adoption of these injections in outpatient procedures is a key trend boosting the market’s growth.
The epidemiology of facet joint pain is a key underpinning for key research and development in the facet joint injections market. More than two thirds of the population globally suffer from back pain, with chronic pain prevalent in young adults. The high incidence and prevalence of chronic spine pain is a key factor boosting the demand in the facet joint injections market. Though in most cases, episodes in the spinal pain are short-lived but in recent years, the recurrence rate is significant-- 28% to 75%, according to several of the recent studies. The high economic burden of facet joint injections in terms of loss of productivity is a key trend boosting the market.
The unmet need of diagnosis of spinal symptoms is a key aspect boosting the facet joint injections market. The use of local anaesthetic with prolonged effect and depot steroid preparations is a key trend boosting the market. Technological strides made in imaging-guided intra-articular injection are expanding the avenue in the facet joint injections market. The growing use of high-quality C-arm fluoroscopy in therapeutic interventions in outpatient procedures has bolstered the prospects in the market.
Growing number of randomized clinical trials for assessing the outcomes of current diagnostic and therapeutic procedures are expanding the competitive landscape in the facet joint injections market. owing to growing burden of non-specific low back pain, companies looking for substantial stakes in the facet joint injections market are leaning on conducting targeted lumbar facet-joint injections. Regulatory agencies have turned their attention toward low back pain on adults. A case in point is updating of guidelines by the National Institute for Health and Care Excellence (NICE) guidelines. A number of multicenter studies in the U.K. have upped the ante for industry players in the market.
Some of the key players in the facet joint injections market are Sigma-Aldrich, Symbiotec Pharmalab Private Limited, Avik Pharmaceuticals Ltd., Bristol-Myers Squibb Company, Bausch Health Companies Inc., Aspen Pharmacare, Henry Schein Medicalt, Pierrel, and Primex Pharmaceuticals Oy.
The facet joint injections market is witnessing substantial revenue streams in North America, Europe, and Asia Pacific. The prospects of facet joint injections have risen on the back of extensive research and development activities focused toward lowering the morbidity and burden of non-specific low back pain in the U.S. have driven the rapid expansion. The opportunities have also seen rapid rise in Europe, expanding on the back of pathophysiology of the facet syndrome. Advances made in diagnosis of the facet syndrome are boosting the growth of the Europe market.